Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Cash & Current Investments: 2009-2024

Historic Cash & Current Investments for Anika Therapeutics (ANIK) over the last 16 years, with Dec 2024 value amounting to $79.2 million.

  • Anika Therapeutics' Cash & Current Investments fell 11.63% to $80.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $311.9 million, marking a year-over-year decrease of 18.60%. This contributed to the annual value of $79.2 million for FY2024, which is 16.70% down from last year.
  • Per Anika Therapeutics' latest filing, its Cash & Current Investments stood at $79.2 million for FY2024, which was down 16.70% from $95.1 million recorded in FY2023.
  • Anika Therapeutics' 5-year Cash & Current Investments high stood at $124.2 million for FY2021, and its period low was $79.2 million during FY2024.
  • Over the past 3 years, Anika Therapeutics' median Cash & Current Investments value was $95.1 million (recorded in 2023), while the average stood at $98.4 million.
  • Per our database at Business Quant, Anika Therapeutics' Cash & Current Investments tumbled by 46.84% in 2020 and then grew by 26.35% in 2021.
  • Yearly analysis of 5 years shows Anika Therapeutics' Cash & Current Investments stood at $98.3 million in 2020, then grew by 26.35% to $124.2 million in 2021, then declined by 2.64% to $121.0 million in 2022, then fell by 21.38% to $95.1 million in 2023, then fell by 16.70% to $79.2 million in 2024.